Targeting the ECM component HA:a new route for mCRC treatment  

作　　者：Wanjing Shang Simone Gottlieb Yikun Yao 

机构地区：[1]Laboratory of Immune System Biology,National Institute of Allergy and Infectious Diseases,National Institutes of Health,Bethesda 20892,USA

出　　处：《Science China(Life Sciences)》2023年第8期1944-1946,共3页中国科学（生命科学英文版）

摘　　要：Colorectal cancer(CRC)is a complex and heterogeneous disease that is the second-leading cause of cancer-related deaths worldwide.Mesenchymal colorectal cancer(m CRC)accounts for about one-third of all CRC.Despite significant advances in understanding the molecular mechanisms underlying m CRC,effective treatments for patients with advanced disease remain limited,particularly for the aggressive mesenchymal subtype of CRC(Rawla et al.,2019).

关 键 词：cancer TREATMENT 

分 类 号：R735.34[医药卫生—肿瘤]